Can a Blood Test Predict Breast Cancer Recurrence After Treatment 8 Months in Advance?

According to a newly reported study, a blood test measuring circulating tumor DNA (ctDNA) can predict breast cancer recurrence 8 months in advance.
Breast cancer, the most common cancer in women, can be completely treated when identified early. Alongside environmental factors such as obesity, alcohol and smoking, genetics also play an important role. Nevertheless, we can reduce the influence of both environmental and genetic factors. Frequent medical checkups, regular examinations and daily changes such as proper, regular eating and exercise can avert breast cancer risk. Hundreds of studies show that prevention, risk reduction and complete recovery with treatment after early detection may be possible.
Today we share one such study, published in Science Translation Medicine. It showed that, among early-stage patients who recovered after treatment but had high recurrence risk, breast cancer recurrence (relapse) could be detected 8 months in advance.
The study enrolled 55 breast cancer patients. First, DNA from tumor cells obtained through biopsy was examined for mutations (genetic changes). Examining the 14 most frequently mutated genes, researchers found among 55 participants that 43 had at least one mutation, while the other 12 had 2 or more gene mutations. Blood samples taken 2-4 weeks after treatment completion were then examined for these mutated tumor DNAs. This early diagnostic method, based on detecting circulating tumor DNA, was shown to identify recurrent cancer much earlier, more easily and more clearly than standard imaging (ultrasound, MRI).
Dear friends, although the study is striking, recurrence risk is not the same for every patient. We know which patients described as completely recovered through chemotherapy and surgery have higher recurrence risk. Such testing would help this group. We will closely follow whether it can be used and its availability in the coming period.
Sources
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.
Science Translational Medicine 26 Aug 2015: Vol. 7, Issue 302, pp. 302ra133. DOI: 10.1126/scitranslmed.aab0021
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.